A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti‐interferon γ antibody, in patients with moderate to severe Crohn's disease

INTRODUCTION: This study was designed to evaluate the safety of fontolizumab, a humanised anti‐interferon γ antibody, in patients with moderate to severe Crohn's disease (CD). PATIENTS AND METHODS: Forty five patients with a CD activity index (CDAI) of 250–450 were randomised in a double blind,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reinisch, W, Hommes, D W, Van Assche, G, Colombel, J‐F, Gendre, J‐P, Oldenburg, B, Teml, A, Geboes, K, Ding, H, Zhang, L, Tang, M, Cheng, M, van Deventer, S J H, Rutgeerts, P, Pearce, T
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2006
Assuntos:
Inflammatory Bowel Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856289/
https://ncbi.nlm.nih.gov/pubmed/16492717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.079434
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados